Travere Therapeutics (TVTX) Other Non-Current Assets (2013 - 2026)
Travere Therapeutics posted quarterly Other Non-Current Assets of $8.5 million for Q1 2026, down 54.65% year-on-year from $18.7 million in Q1 2025, and down 4.55% on a QoQ basis from $8.9 million in Q4 2025.
Travere Therapeutics (TVTX) has 14 years of Other Non-Current Assets data on file, last reported at $8.5 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 54.65% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $8.5 million (down 54.65% YoY), and the FY2025 full-year result was $8.9 million, down 51.11% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $8.5 million, down from $8.9 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $48.3 million in Q4 2022 and bottomed at $8.5 million in Q1 2026.
- The 5-year median for Other Non-Current Assets is $11.4 million (2022), against an average of $15.8 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets surged 336.73%; it then slumped 77.95% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $48.3 million in 2022, then plunged by 77.95% to $10.7 million in 2023, then jumped by 70.36% to $18.2 million in 2024, then plunged by 51.11% to $8.9 million in 2025, then declined by 4.55% to $8.5 million in 2026.
- The last three Other Non-Current Assets figures came in at $8.5 million (Q1 2026), $8.9 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Travere Therapeutics | 4.14 Bn | 4.06 Bn | 102.38 Mn | 8.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.48 Mn |
| Dec 31, 2025 | 8.88 Mn |
| Sep 30, 2025 | 10.25 Mn |
| Jun 30, 2025 | 19.65 Mn |
| Mar 31, 2025 | 18.69 Mn |
| Dec 31, 2024 | 18.16 Mn |
| Sep 30, 2024 | 17.12 Mn |
| Jun 30, 2024 | 16.92 Mn |
| Mar 31, 2024 | 19.30 Mn |
| Dec 31, 2023 | 10.66 Mn |
| Jun 30, 2023 | 11.79 Mn |
| Mar 31, 2023 | 11.03 Mn |
| Dec 31, 2022 | 48.34 Mn |
| Sep 30, 2022 | 11.09 Mn |
| Jun 30, 2022 | 10.81 Mn |
| Mar 31, 2022 | 10.83 Mn |
| Dec 31, 2021 | 11.07 Mn |
| Sep 30, 2021 | 34.87 Mn |
| Jun 30, 2021 | 34.36 Mn |
| Mar 31, 2021 | 35.03 Mn |
| Dec 31, 2020 | 7.81 Mn |
| Sep 30, 2020 | 33.69 Mn |
| Jun 30, 2020 | 13.90 Mn |
| Mar 31, 2020 | 6.80 Mn |
| Dec 31, 2019 | 14.71 Mn |
| Sep 30, 2019 | 12.45 Mn |
| Jun 30, 2019 | 12.70 Mn |
| Mar 31, 2019 | 13.47 Mn |
| Dec 31, 2018 | 7.71 Mn |
| Sep 30, 2018 | 7.39 Mn |
| Jun 30, 2018 | 5.35 Mn |
| Mar 31, 2018 | 6.46 Mn |
| Dec 31, 2017 | 5.56 Mn |
| Sep 30, 2017 | 7.10 Mn |
| Jun 30, 2017 | 3.63 Mn |
| Mar 31, 2017 | 3.66 Mn |
| Dec 31, 2016 | 7.36 Mn |
| Sep 30, 2016 | 1.97 Mn |
| Jun 30, 2016 | 1.86 Mn |
| Mar 31, 2016 | 1.86 Mn |
| Dec 31, 2015 | 1.86 Mn |
| Sep 30, 2015 | 2.01 Mn |
| Jun 30, 2015 | 2.02 Mn |
| Mar 31, 2015 | 1.99 Mn |
| Dec 31, 2014 | 2.27 Mn |
| Sep 30, 2014 | 1.92 Mn |
| Dec 31, 2013 | 244,058.00 |
| Sep 30, 2013 | 2.25 Mn |